{"created":"2023-06-20T15:46:12.083203+00:00","id":791,"links":{},"metadata":{"_buckets":{"deposit":"b8739574-c0b8-49a0-aa65-81608a4adb4a"},"_deposit":{"created_by":4,"id":"791","owners":[4],"pid":{"revision_id":0,"type":"depid","value":"791"},"status":"published"},"_oai":{"id":"oai:uoeh-u.repo.nii.ac.jp:00000791","sets":["13:17:18"]},"author_link":["2942","2937","2941","2935","2938","2939","2940","2943","2936","2934"],"item_10001_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2018-03-01","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"9","bibliographicPageStart":"1","bibliographicVolumeNumber":"40","bibliographic_titles":[{"bibliographic_title":"産業医科大学雑誌"},{"bibliographic_title":"Journal of UOEH","bibliographic_titleLang":"en"}]}]},"item_10001_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Our purpose was to determine the effects of teneligliptin and sitagliptin, two dipeptidyl peptidase 4 inhibitors (DPP4-Is) with different half-lives, on glycemic variability and glucagon-like peptide-1 (GLP-1) levels in Japanese patients with type 2 diabetes mellitus (T2DM). The study subjects were 14 drug-naïve patients with T2DM who were allocated to either a 20 mg/day teneligliptin group (n = 7) or a 50 mg/day sitagliptin group (n = 7) for 7 days, then switched to the other treatment for another 7 days. Meal tolerance tests were performed at the time of no treatment, and after treatment with each DPP4-Is at supper. We evaluated the effects of each drug on glucose fluctuation using continuous glucose monitoring (CGM). There was no significant difference between the two groups in the primary endpoint (maximum glucose level after supper), nor in the secondary endpoint: area under the curve (AUC) for plasma glucose (≥140 mg/dl) after supper (18:00 - 24:00). Teneligliptin significantly improved the AUC for plasma glucose (≥140 mg/dl) after supper (20:00-24:00) (P = 0.048), and also significantly increased the GLP-1 level at 30 minutes after the meal load (P = 0.030). No serious adverse effects were noted in either group, apart from a few episodes of asymptomatic hypoglycemia. A daily dose of teneligliptin improved the AUC for plasma glucose at 20:00 to 24:00 (≥140 mg/dl) after the meal tolerance test, and also significantly increased the levels of activated GLP-1 after the test meal.","subitem_description_type":"Abstract"},{"subitem_description":"今回我々は，日本人2型糖尿病患者において，半減期の異なるdipeptidyl peptidase 4（DPP4）阻害薬であるテネリグリプチンとシタグリプチンによる血糖変動とglucagon like peptide-1（GLP-1）分泌に対する効果に関して検討した．14 名の薬剤未使用2型糖尿病患者をテネリグリプチン20 mg先行群（7名）もしくはシタグリプチン50 mg先行群（7名）へ無作為に割り付けクロスオーバーで7日間ずつ内服した． 食事負荷試験は夕食時に薬剤なし，それぞれのDPP4阻害薬内服下で施行した．各薬剤の血糖変動に対する効果は，continuous glucose monitoring（CGM）を用いて評価した．主要評価項目である夕食後最大血糖値は2群間で有意差は認めなかった．副次評価項目である夕食後18:00- 24:00における血糖値140 mg/dl 以上のarea under the curve（AUC）は2群間で有意差は認めなかったが，夕食後20:00- 24:00における血糖値140 mg/dl 以上のAUCはテネリグリプチンの方が有意にコントロール良好であった（P=0.048）．また食事負荷30分後のGLP-1はテネリグリプチンの方が有意に高値であった（P=0.030）．数例で無症候性の低血糖を認めたが，両薬剤とも重大な有害事象は認めなかった．1日1回内服のテネリグリプチンは，食事負荷試験において20:00- 24:00における血糖値140 mg/dl 以上のAUCを改善させ，活性型GLP-1を増加することが明らかとなった．","subitem_description_type":"Abstract"}]},"item_10001_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"産業医科大学（産業医科大学学会）"}]},"item_10001_relation_17":{"attribute_name":"関連サイト","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"Journal of UOEH"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://www.jstage.jst.go.jp/browse/juoeh/40/1/_contents/-char/ja","subitem_relation_type_select":"URI"}},{"subitem_relation_name":[{"subitem_relation_name_text":"産業医科大学雑誌"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://www.uoeh-u.ac.jp/kouza/journal/i_2018-1j.html","subitem_relation_type_select":"URI"}}]},"item_10001_select_24":{"attribute_name":"記事区分","attribute_value_mlt":[{"subitem_select_item":"Original"}]},"item_10001_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"ISSN 0387-821X(PRINT), ISSN 2187-2864(ONLINE)","subitem_source_identifier_type":"ISSN"}]},"item_10001_version_type_20":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"黒住, 旭"}],"nameIdentifiers":[{"nameIdentifier":"2934","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"岡田, 洋右"}],"nameIdentifiers":[{"nameIdentifier":"2935","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"須貝, 彗"}],"nameIdentifiers":[{"nameIdentifier":"2936","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"鳥本, 桂一"}],"nameIdentifiers":[{"nameIdentifier":"2937","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"田中, 良哉"}],"nameIdentifiers":[{"nameIdentifier":"2938","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kurozumi, Akira","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"2939","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Okada, Yosuke","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"2940","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Sugai, Kei","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"2941","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Torimoto, Keiichi","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"2942","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Tanaka, Yoshiya","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"2943","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-03-18"}],"displaytype":"detail","filename":"S00040101.pdf","filesize":[{"value":"1.0 MB"}],"format":"application/pdf","licensetype":"license_11","mimetype":"application/pdf","url":{"label":"S00040101.pdf","url":"https://uoeh-u.repo.nii.ac.jp/record/791/files/S00040101.pdf"},"version_id":"06480f40-0c40-4689-b4b2-19c4d4d942ac"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"グルカゴン様ペプチド-1","subitem_subject_scheme":"Other"},{"subitem_subject":"持続血糖モニタリング","subitem_subject_scheme":"Other"},{"subitem_subject":"ジペプチジルペプチダーゼ 4阻害薬","subitem_subject_scheme":"Other"},{"subitem_subject":"glucagon like peptide-1","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"continuous glucose monitoring","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"dipeptidyl peptidase 4 inhibitors","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"2 型糖尿病患者における半減期の異なる2種類のdipeptidyl peptidase 4阻害薬テネリグリプチンとシタグリプチンの血糖変動およびGLP-1に対する効果の比較検討","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"2 型糖尿病患者における半減期の異なる2種類のdipeptidyl peptidase 4阻害薬テネリグリプチンとシタグリプチンの血糖変動およびGLP-1に対する効果の比較検討"},{"subitem_title":"Comparison of the Effects of Teneligliptin and Sitagliptin, Two Dipeptidyl Peptidase 4 Inhibitors with Different Half-Lives, on Glucose Fluctuation and Glucagon-Like Peptide-1 in Type 2 Diabetes Mellitus","subitem_title_language":"en"}]},"item_type_id":"10001","owner":"4","path":["18"],"pubdate":{"attribute_name":"公開日","attribute_value":"2020-08-03"},"publish_date":"2020-08-03","publish_status":"0","recid":"791","relation_version_is_last":true,"title":["2 型糖尿病患者における半減期の異なる2種類のdipeptidyl peptidase 4阻害薬テネリグリプチンとシタグリプチンの血糖変動およびGLP-1に対する効果の比較検討"],"weko_creator_id":"4","weko_shared_id":-1},"updated":"2023-06-20T15:57:00.188284+00:00"}